ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Pharmaceutical Preparations

Latest Price

$205.48

TTM P/E

88.19

Normalized P/E

Div Yield

Book Value

1.79

P/B Ratio

114.72

Valuation metrics

EPS: $2.33

Book value / share: $5.96

Formula: √(22.5 × EPS × BVPS)

Graham Number

$17.68

91% downside

Base FCF: $254M (median of recent 5yr)

Growth: 5%/yr (median YOY, capped at 25%)

Discount rate: 10%

Terminal growth: 3%

Projection horizon: 10 years

DCF Fair Value

$45.20

78% downside

EPS: $2.33

Target P/E: 88×

Formula: EPS × P/E

P/E Fair Value

$205.04

0% downside

90.7% held by institutions

Institution	Shares	Value	Ownership %	Change	Filing Date
FMR LLC	14.58M	$4.82B	11.01%	-1.32M	2026-03-31
Capital World Investors	10.80M	$3.57B	8.16%	-5.50M	2026-03-31
BlackRock, Inc.	10.44M	$3.46B	7.89%	+44.0K	2026-03-31
Capital Research Global Investors	9.47M	$3.13B	7.15%	+2.69M	2026-03-31
VANGUARD PORTFOLIO MANAGEMENT LLC	6.49M	$2.15B	4.90%	--	2026-03-31
VANGUARD CAPITAL MANAGEMENT LLC	5.95M	$1.97B	4.49%	--	2026-03-31
T. Rowe Price Investment Management, Inc.	5.19M	$1.72B	3.92%	+4.04M	2026-03-31
STATE STREET CORP	3.32M	$1.10B	2.51%	+93.7K	2026-03-31
GEODE CAPITAL MANAGEMENT, LLC	2.66M	$884.0M	2.01%	+9.7K	2026-03-31
BAILLIE GIFFORD & CO	2.49M	$825.0M	1.88%	-107.1K	2026-03-31